In the Margins

Sequoia Fund's Valeant bet highlights concentration risks

November 2, 2015

By The Wall Street Journal

Concentrated bets on individual stocks raise issues for mutual funds and their investors—a matter highlighted last week at Sequoia Fund, one of the biggest investors in controversial drug maker Valeant Pharmaceuticals International Inc. Placing outsize bets on well-chosen stocks can lead to strong performance, but concentration increases the riskiness of a fund and raises questions about how much is too much. Read the original story from The Wall Street Journal.

 

 

Most Read

Viewpoints
Op-Ed: Whither valuation guidance?

The Securities and Exchange Commission should issue valuation guidance for investment companies. When I was chief counsel in the SEC's Division of Investment Management from 1997 ...